Business Context and Reporting Period
This Form 8-K Current Report was filed by NanoVibronix, Inc. (not Envue Medical, Inc.) on June 8, 2017. The registrant is a Delaware corporation headquartered in Elmsford, New York, and is classified as an emerging growth company. The filing discloses the entry into a material definitive agreement involving the issuance of debt and equity-linked securities to an accredited investor.
Key Financial Metrics and Transaction Details
- Debt Issuance: The Company issued a convertible promissory note with a principal amount of $500,000.
- Interest Rate: Notes bear interest at 6% per annum, payable in arrears on the Maturity Date.
- Warrant Issuance: A seven-year warrant was issued to purchase 200,000 shares of common stock.
- Exercise Price: The warrant exercise price is set at $5.90 per share.
- Recent Activity: Similar notes ($25,000 principal) and warrants (10,000 shares) were issued on June 2, 2017, and May 28, 2017.
- Liquidity and Cash Flow: The filing text does not provide specific values for current cash balances, operating cash flow, or total liquidity.
- Revenue and Profit: The filing text does not provide revenue, profit, or margin data.
Material Changes and Terms
The primary material change is the creation of a direct financial obligation and the potential dilution of existing shareholders through the issuance of the Note and Warrant. Key terms include:
- Maturity Date: The earlier of the 5-year anniversary of issuance or the date of a "Qualified Financing" (aggregate proceeds of at least $2,000,000).
- Conversion Rights: Upon maturity or a Qualified Financing, investors may convert principal and accrued interest into common stock or Series C Convertible Preferred Stock.
- Conversion Price: The price per share is the lesser of 80% of the estimated company value (or Qualified Financing price) or the $5.90 cap.
- Change of Control: Investors have the option to receive cash or convert at a discounted rate (lesser of 80% of implied value or $5.90) in the event of a change of control.
- Exercise Limitations: Warrants are immediately exercisable but subject to a 9.99% beneficial ownership limitation unless the holder adjusts the limit with 61 days' notice.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or management commentary regarding future performance. However, it highlights the following risks and contingencies:
- Dilution Risk: The conversion of notes and exercise of warrants will increase the number of outstanding shares, potentially diluting existing shareholders.
- Financing Contingency: The debt obligation accelerates upon the completion of a Qualified Financing, which may impact the terms of future equity raises.
- Valuation Uncertainty: Conversion prices in certain scenarios depend on the "estimated value of the Company" as determined in good faith by the board of directors.
- Registration Rights: Warrants may be exercised on a cashless basis if no effective registration statement is available after six months.
Investor Verification Checklist
- Verify the total outstanding principal amount of all convertible notes issued in May and June 2017.
- Confirm the current number of outstanding shares of common stock to assess the potential dilution impact of the 200,000 warrant shares and note conversions.
- Review the Company's recent cash burn rate and runway to determine the likelihood of a "Qualified Financing" triggering early maturity.
- Examine the full text of Exhibits 10.1 (Form of Note) and 10.2 (Form of Warrant) for specific anti-dilution provisions and adjustment mechanisms.
- Check for any subsequent filings regarding the status of the Qualified Financing or changes in the Company's capital structure.